Doxorubicin Market

Doxorubicin Market Outlook 2031

The global doxorubicin market size was USD 1.24 Billion in 2022 and is estimated to reach USD 2.08 Billion by 2031 expand at a substantial CAGR 5.9% during the forecast period, 2023–2031. The growth of the market is attributed to the rising government initiatives, growing investment in advanced technology in clinical oncology such as intravenous therapy and digital microfluidics for on chip biological analysis.

Doxorubicin is an anthracycline antibiotic for anti-cancer chemotherapy drugs, rubex and adriamycin. It is produced from a natural substance produced by the bacteria Streptomyces peucetius var. caesius and belongs to the antineoplastic class of anti-cancer medications. Breast, ovary, stomach, bone, bladder, testicles, lung, osteogenic sarcoma, soft tissue, Wilms' tumor, and Hodgkin's & non-lymphomas Hodgkin's are among the area of cancers for which doxorubicin is used for the treatment. It is also utilized in the treatment of squamous cell carcinomas of the head and neck less commonly.

Get Free Sample Report

Furthermore, doxorubicin intercalates between the base pairs in the deoxyribonucleic acid (DNA) helix, blocking DNA replication, decreasing protein synthesis, and reduces the rate of growth of malignant cells. This drug is delivered intravenously using peripheral inserted central line catheters or central venous catheters and is available in injectable solution & lyophilized powder form.

The amount of this medicine is determined by the type and severity of cancer as well as the type of other medications used during therapy. According to the American Cancer Society (ACS), it was reported that about 38 million people die every year due to non-communicable diseases, with more than 8 million of them are dying from tumor malignancy.

Furthermore, based on the estimates of the World Health Organization (WHO), the cancer incidence rate could further increase by 50% by 2020. The rising use of the drug to treat AIDS related Kaposi Sarcoma, breast malignancy, multiple myeloma, and acute meroblastic leukemia are the pivotal factors expected to boost the doxorubicin market value.

Doxorubicin Market Trends, Drivers, Restraints, and Opportunities

• Increasing application of doxorubicin and rising number of companies manufacturing doxorubicin are expected to fuel the market growth.
• Rising geriatric population across the world is another factor of growing prevalence of blood cancer. This is expected to boost the market growth in the coming years.
• Development of pre-clinical and clinical research along with the advancement in therapeutics coupled with the presence of robust product pipeline are anticipated to drive market growth.
• Formation of new rules and regulations from government bodies encouraging for the development of new drugs for blood cancer are estimated to propel the market.
• Less awareness among the people related to different types of cancers is another key challenge that can hinder the market growth during the forecast period.
• Increasing expenditures and high cost investment in the treatment process are likely to hamper the market growth.
• Early stage approval from regulatory bodies for cancer treatment drugs is projected to be a great opportunity for pharmaceutical companies in near future. This is estimated to upsurge the market growth.

Scope of The Doxorubicin Market Report

The report on the global doxorubicin market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Doxorubicin Market Segment Insights

Breast cancer segment is projected to expand at a considerable CAGR

On the basis of applications, the global doxorubicin market is segmented into kidney, liver, breast, ovarian, leukemia, multiple myeloma, kaposi sarcoma, bone sarcoma, endometrial, gastric, and other cancers. The breast cancer segment is projected to expand at a considerable CAGR during the forecast period owing to the rising demand for the breast cancer treatment in the market.

Cancer has surpassed heart disease as the vital cause of death worldwide, with an estimated 9.6 million deaths in 2018. According to WHO, cancer is responsible for around one out of every six deaths globally.

According to the organization, the number of cases of breast cancer in 2018 was approximately 2.09 million, which was close to the number of lung cancer cases reported that year. As per the American Cancer Institute (ACI), doxorubicin is a chemo medication used to treat advanced breast cancer. Furthermore, in the US, it is estimated that 3 million women have been diagnosed with breast cancer. Thus, it is projected to fuel the segment growth in coming years.

Get Free Sample Report

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share in the coming years due to the growing number of cancer incidences and rising demand for the doxorubicin in combination, and mono chemotherapies in the region.

In the year 2020, the doxorubicin market in the US was expected to be worth USD 402.7 million. In the worldwide market, the country currently holds nearly 40.56% of the combined stake.

Get Free Sample Report

Segments

The global doxorubicin market has been segmented on the basis of

Applications

• Kidney
• Liver
• Breast
• Ovarian
• Leukemia
• Multiple Myeloma
• Kaposi Sarcoma
• Bone Sarcoma
• Endometrial
• Gastric
• Other Cancers

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Cadila Pharmaceuticals
• Sun Pharmaceutical Industries Ltd.
• SRS Pharmaceuticals Pvt. Ltd.
• Pfizer, Inc.
• Cipla, Inc.
• Johnson & Johnson
• Zydus Cadila

Competitive Landscape

Some of the key players competing in the market are Cadila Pharmaceuticals; Sun Pharmaceutical Industries Ltd., SRS Pharmaceuticals Pvt. Ltd.; Pfizer, Inc.; and Cipla, Inc.

Key players in the doxorubicin market are focusing on marketing strategies such as expansion of their product portfolio, merger & acquisition, and collaboration & partnerships by offering latest version of devices to gain substantial share in the market. New competitors in the market are focusing on advanced and affordable alternatives to existing products in order to take advantage of the market potential available in the developing countries.

For example, Aeterna Zentaris announced in 2015 that patient enrollment for the ZoptEC phase 3 clinical study with Zoptarelin Doxorubicin for advanced endometrial cancer cases had been completed.